Navigation Links
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Date:8/13/2008

SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the completion of a $19 Million equity financing. New investors Caxton Advantage Life Sciences Fund (New York, NY) and HBM BioCapital (Cayman Islands) led the financing, and Rachel Leheny, Ph.D. Managing Director of Caxton Advantage Venture Partners (the General Partner of Caxton Advantage Life Sciences Fund) will join Anthera's Board of Directors. The financing also included existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation.

In addition, the company announced the appointment of Christopher S. Henney as Chairman of the Board. Dr. Henney has served as an independent director of Anthera since 2006. Dr. Henney is a co-founder of three major publicly held U.S. biotechnology companies: Immunex‚ ICOS and Dendreon‚ and has been associated with the formation of several others. Most recently Dr. Henney has served as Chairman and Chief Executive Officer of Dendreon (Nasdaq: DNDN) and as Chairman of SGX Pharmaceuticals (Nasdaq: SGXP) and of Oncothyreon (Nasdaq: ONTY).

"We are delighted to have Caxton Advantage and HBM, two premier health care funds, lead
'/>"/>

SOURCE Anthera Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... A new way to produce engineered ... current skin grafting technologies, it also speeds up the ... outlined in the October issue of STEM CELLS Translational ... injuries that result from severe burns and chronic wounds. ... regenerative elements. These wounds heal by contraction, with epithelization ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
Breaking Biology Technology:New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3
... (OTC Bulletin Board: CHBT) (,China-Biotics", "the,Company"), a leading ... and distribution of probiotics products,today announced its financial ... year, ended June 30, 2008., First ... 19.5% year-over-year to $11.4 million -- Gross ...
... ... Aug. 14 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... science of healthy aging, today announced,financial results for the quarter ... June 30, 2008 was $691,000, compared with,$471,000 reported in the ...
... drugs and devices that have ... the quality of human life -, PALO ALTO, Calif., ... announced that its chronic angina therapy,Ranexa(R) (ranolazine extended-releases tablets) has ... 2008 award which honors the,best pharmaceutical agent and best biotechnology ...
Cached Biology Technology:China-Biotics, Inc. Reports First Quarter 2009 Financial Results 2China-Biotics, Inc. Reports First Quarter 2009 Financial Results 3China-Biotics, Inc. Reports First Quarter 2009 Financial Results 4China-Biotics, Inc. Reports First Quarter 2009 Financial Results 5China-Biotics, Inc. Reports First Quarter 2009 Financial Results 6China-Biotics, Inc. Reports First Quarter 2009 Financial Results 7China-Biotics, Inc. Reports First Quarter 2009 Financial Results 8China-Biotics, Inc. Reports First Quarter 2009 Financial Results 9China-Biotics, Inc. Reports First Quarter 2009 Financial Results 10China-Biotics, Inc. Reports First Quarter 2009 Financial Results 11Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 2CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award 3
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... A custom-built, $2.5 million "split magnet" system with the potential ... made its debut at the National High Magnetic Field Laboratory ... at 25 tesla, easily besting the 17.5 tesla French record ... for early 20th-century inventor and engineer Nikola Tesla, is a ...
... as a preventative measure only achieve a short-term effect with ... up with even more aphids than untreated fields. This has ... of Wrzburg in the scientific journal PLoS One . ... triticale fields? This is what the biologists at the Department ...
... widely known PSA blood test for prostate cancer in men ... for breast cancer, the most common form of cancer in ... the ACS journal Analytical Chemistry . Chien Chou ... the test also is a potential biomarker of breast cancer ...
Cached Biology News:25 Tesla, world-record 'split magnet' makes its debut 225 Tesla, world-record 'split magnet' makes its debut 3Fewer aphids in organic crop fields 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: